Publication for CD3D and LCK

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	CD3D	CD3d molecule	915			[link]
hsa	LCK	LCK proto-oncogene, Src family tyrosine kinase	3932

Pubmed ID	Priority	Text
21078154	0.98	CD3delta, CD3epsilon, CD3zeta), protein-tyrosine kinases (e.g., Fyn, Lck, ZAP-70), protein-phosphotyrosine phosphatases (CD45, and others), etc.
23885256	0.98	CD3delta, may confer preference to CD3epsilon in the ITAM phosphorylation cascade upon Lck recruitment by CD4 (Figure 4A).
26043137	0.98	CD3 delta, epsilon, gamma chains, and the associated kinases Lck, and ZAP-70 is not well established.
30483789	0.97	LCK proto-oncogene, Src family tyrosine kinase (LCK), and at its core was predominantly correlated with the regulation of developmental events, notably in the nervous system (Fig. 2A; middle circle); iii) a sub-cluster including interleukin (IL)2 receptor, gamma chain (IL2RG) and CD3d molecule (CD3D), and at its core was primarily associated with immunodeficiency (Fig. 2A; bottom circle).
	0.97	CD3D (8.65), CXCR4 (10.86), IL2RG (9.27), IL7R (8.11), LCK (6.58) and STAT1 (7.36) were determined (Fig. 3A-F and Table II).
	0.92	CD3D, IL2RG, IL7R, LCK and STAT1) were included in the PPI network.
	0.90	LCK, IL2RG and CD3D may represent potential biomarkers associated with immunodeficiency in RA.
	0.89	CD3D, (B) CXCR4, (C) IL2RG, (D) IL7R, (E) LCK, (F) STAT1 and (G) IL7R+STAT1 are presented.
	0.87	CD3D, CXCR4, IL2RG, IL7R, LCK and STAT1) was identified and presented in Fig. 2B, which suggested that these six genes may represent important biomarkers associated with RA and OA development and diagnosis.
	0.80	CD3D, IL2RG, IL7R, LCK and STAT1 may activate the primary immunodeficiency pathway and subsequently lead to primary immune system dysfunction and the development of RA.
	0.71	CD3D, T-cell surface glycoprotein CD3 delta chain; CXCR4, C-X-C motif chemokine receptor 4; IL2RG, interleukin 2 receptor gamma; IL7R, interleukin 7 receptor; LCK, LCK proto-oncogene, Src family tyrosine kinase; STAT1, signal transducer and activator of transcription 1.
	0.60	CD3D (0.8357), CXCR4 (0.7855), IL2RG (0.8368), IL7R (0.9161), LCK (0.8683) and STAT1 (0.9138; all P<0.0001).
	0.57	CD3D, T-cell surface glycoprotein CD3 delta chain; CXCR4, C-X-C motif chemokine receptor 4; IL2RG, interleukin 2 receptor gamma; IL7R, interleukin 7 receptor; LCK, LCK proto-oncogene, Src family tyrosine kinase; STAT1, signal transducer and activator of transcription 1.
29977931	0.97	lymphocyte kinase (LCK), CD3G, B2M, interferon-gamma, CD3D, tumor necrosis factor, VAV1, and CD3E in the T cell receptor signaling pathway were selected as important factors, and LCK was identified as the hub protein.
	0.96	LCK, CD3G, B2M, IFNG, CD3D, TNF, VAV1, and CD3E, were put into GenCLiP 2.0 for analysis of Gene Cluster with Literature Profiles and Literature Mining Gene Networks.
	0.91	LCK, CD3G, CD3E, CD3D, IFNG, VAV1, TNF, B2M, CXCR3, CCR5, CCL5, CXCL9, CXCL10, CXCR4, GNG2, IL1B, IL12B, IL2RB, IL2RA, IL2RG, STAT1, CD8A, CD86, PTPRC, PIK2CG, CD44, and HLA-DPA1 and 1 downregulated protein EGF.
	0.88	LCK, CD3G, B2M, IFNG, CD3D, TNF, VAV1, and CD3E in previous studies.
23071622	0.97	Lck, ZAP70, and CD3 delta, epsilon, xi ITAMs, and the variation of this effect over time is consistent with a model of SLP-76 regulation of competing positive and negative feedback loops (Figure 1 and Figure 8).
	0.88	Lck at its activation tyrosine residue Tyr394, CD3 delta, epsilon, zeta at their respective ITAMs, ZAP70 at the activating site Tyr394 as well as several other tyrosine residues, was significantly elevated at the early timepoints and significantly reduced phosphorylation at later timepoints in the SLP-76 deficient Jurkat T cells (Figure 8).
29140996	0.97	CD3D, CD3G, TCRalpha) and downstream signalling molecules (LAT, LCK, ITK, Ras GRP and NFAT).
	0.78	CD3D, LAT, LCK, NFATC2) and one showing no change (NFATC3).
24293448	0.97	CD3D, CD3E, CD8A, CD8B, CD247), (b) T-cell chemotaxis and migration to inflamed tissues (CXCR3), (c) T-helper lineage development (GATA3, STAT4, TBX21), (d) T-cell activation, proliferation, development, signal transduction, survival, and cytokine production (CCR7, CD6, CD28, DPP4, IL23A, IL23R, IL2RB, IL5RA, IL9R, ITK, LCK, PRKCQ, TCF7, ZAP70), (e) generation and long-term maintenance of T-cell immunity (CD27), (f) T-cell-mediated cytotoxicity (GNLY, GZMA), and (g) regulation of B-cell activation, V(D)J recombination, and Ig synthesis (CCR7, IL7R).
28644030	0.97	Lck kinase activity was slightly elevated with PLC-gamma1 deficiency, the constitutive and significant decrease in phosphorylation on Lck substrate ITAM sites on zeta and CD3delta, epsilon, and gamma as well as the aforementioned Lck-regulated activation sites on Zap-7 indicates that phosphorylation of canonical Lck substrates is impaired in Jgamma1.
22151962	0.96	CD3D, CD48, GZMB, LCK, MS4A1, PRF1, and SELL) and used unsupervised hierarchical clustering to examine the association between TIL and short-term response to neoadjuvant chemotherapy in a previously published cohort of ER-negative tumors (n = 113).
	0.96	CD3D, CD48, GZMB, LCK, MS4A1, PRF1, and SELL (see Methods), that was used in subsequent analyses.
	0.94	CD3D, LCK, CD48, SELL, GZMB, PRF1).
26215705	0.96	CD3D, CD3G, CD4, CD8A, FYN, ITK, LCK, NFATC2, NFATC3, PAG1, PRKCQ, and VAV2) or to some activation pathway like glucocorticoid receptor signaling (BCL2, CCL5, CD163, CD247, CD3D, CD3G, IL8, NFATC2, NFATC3, and PRKAA1) or p53 signaling (BCL2, PTEN, THBS1, and TP53).
31057561	0.96	LCK, T cell receptor zeta chain CD247, its interacting Src kinase ZAP70, TCR associated CD3 family members (CD3D, CD3E, and CD3G), co-signaling receptors CTLA4 and PDCD1, TCR adapter proteins LAX1 and SLA2, and CD8A.
26871470	0.95	CD3D, CD3E, LCK, LCP2, CD247, HLA-DPB1, HLA-DOB, ITK, PTPRC), the IFN-gamma pathway (STAT6, TFF3, PRKCA, TGFBR2, PIM1, PRKCH, PRKCQ, IRF4) and the TNFR pathway (TRAF1, PRF1, MAPKAPK3, TNFRSF1B, CCM2, GZMB, BIRC3, MAP3K14), and we assessed whether they were differentially expressed between tumors with high neoantigen load versus those with low antigen load (lowest quartile).
23096155	0.93	CD3delta, CD247), LAT, TCR signaling molecules (protein kinase c theta (PRKCQ), protein tyrosine phosphatase receptor type C (PTPRC), C-SRC tyrosine kinase (CSK), SYK, lymphocyte-specific protein tyrosine kinase (LCK)), integrins CD2, CD44, integrin alpha L, M and X (ITGAL, ITGAM, ITGAX) and cyclin D3 (CCND3) (Supplementary Figure S2B, Table 1 and Supplementary Table S5).
18485203	0.92	CD3D, CD3G, TRAT1, ITGAL, ITGB1, ITGB2, CD8A and CD8B (CD8+ T-cell specific) along with LCK, ZAP70 and TYROBP, were all simultaneously downregulated.
	0.83	CD3D, CD3G, TRAT1, ITGAL, ITGB1, ITGB2, CD8A and B (CD8+ T-cell specific) along with LCK, ZAP70 and TYROBP were synchronously downregulated.
21910250	0.91	CD3D, CD3G, CD6, LCK, LAX1, SIT1, RHOH, UBASH3A and ICOS; Fig 6A).
28026094	0.91	CD3D), protein tyrosine kinase (PTK) genes (LCK, ITK, TXK), the Grb-2-related adaptor protein 2 (GRAP2), and the adapter proteins SIT1 (signaling threshold regulating transmembrane adaptor 1) and SLA2 (Scr-like adaptor 2), which negatively regulate TCR signaling.
28863153	0.91	CD3D, ITK, CTLA4, LCK, RASGRP1).
31711503	0.75	CD3 delta, CD28, CTLA-4, transcription factor 7 (TCF7), and nonreceptor protein-tyrosine kinase p56 (LCK) (Fig. 4a).
32034137	0.75	LCK (1st panel) and CD3D (2nd panel), two known T-cell markers.
15067034	0.61	CD3 delta, e, and gamma chains and in the TCR zeta chain by the Src family protein tyrosine kinase Lck.
29967623	0.60	CD3D/NFATC2/CD3E/LCK/CD3G panel, and FASLG/CD8A/PRF1/granzyme B panel.